clinical trial · NCT05483907
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
Bridge Biotherapeutics, Inc.·phase2·completed·n = 129
Idiopathic Pulmonary FibrosisBBT-877Placebo
brief summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
started
Apr 12, 2023
primary completion
Jan 26, 2025
completion
Feb 23, 2025
last updated
Apr 1, 2025
official title
A Phase 2, Randomized, Double-blind, Placebo-controlled, 24-Week Study to Evaluate the Efficacy, Safety, and Tolerability of BBT-877, as Mono- or add-on Therapy, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol